Menu Search
Equities

Onconetix Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
J4T:MUN

Onconetix Inc

Actions
  • Price (EUR)2.60
  • Today's Change0.00 / 0.00%
  • Shares traded133.00
  • 1 Year change--
  • Beta3.4266
Data delayed at least 15 minutes, as of Dec 01 2025 12:38 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

  • Revenue in USD (TTM)1.22m
  • Net income in USD-50.85m
  • Incorporated2018
  • Employees5.00
  • Location
    Onconetix Inc201 E. Fifth Street, Suite 1900CINCINNATI 45202United StatesUSA
  • Phone+1 (302) 497-7115
  • Fax+1 (845) 818-3588
  • Websitehttps://www.onconetix.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ONCO:NAQ since
announced		Transaction
value
Ocuvex Therapeutics IncDeal completed08 Apr 202508 Apr 2025Deal completed-76.18%--
Data delayed at least 15 minutes, as of Feb 11 2026 16:39 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.